Peter Irving

Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial

1 Nancy University Hospital, Vandoeuvre-les-Nancy, France; 2 GI Alliance, United States; 3 Icahn School of Medicine at Mount Sinai, New York, United States; 4 UNIMI, Department of Pathoph...

Xiu Huang ;

Sofie Berg ;

Lei Shu ;

Kristina Kligys ;

Remo Panaccione ;

Marc Ferrante ;

Britta Siegmund ;

Jean-Frederic Colombel ;

Ezequiel Neimark ;

Geert D'Haens ;

Kori Wallace ;

Marla C. Dubinsky , MD;

Peter Irving ;

W. Rachel Duan ;

Flavio Caprioli ;

Stefan Schreiber ;

Laurent Peyrin-Biroulet ;

Raja Atreya ;

Silvio Danese ;

James O. Lindsay ;

Casey Chapman ;

Peter Bossuyt ;

Toni Anschutz ;

Valerie Pivorunas ;

01/11/2024

P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial

BACKGROUND: Ozanimod is an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P 1 and S1P ...

Silvio Danese ;

Subrata Ghosh ;

AnnKatrin Petersen ;

Jean-Frederic Colombel ;

Geert D'Haens ;

Peter Irving ;

Denesh Chitkara ;

Cecilia Marta ;

Tianlei Chen ;

Lorna Charles ;

12/15/2021

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Peter Irving

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products